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 2012 Australian Society for Parasitology Published by Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction developed and used to screen a library of bioactive compounds.This special issue of IJPDDR provides a sampling of the research
presented in January, 2012, at the Keystone Symposium on ‘‘Drug
Discovery for Protozoan Parasites’’ held in Santa Fe, New Mexico.
The symposium on this topic has taken place approximately every
2 years since its inception in 2002. As in previous years, the meet-
ing provided a forum for leading investigators around the world to
present data covering basic sciences to clinical trials relating to
anti-protozoan drug development and drug resistance. As would
be expected, many talks focused on malaria, but other protozoan
diseases receiving attention included African sleeping sickness,
Chagas disease, leishmaniasis, cryptosporidiosis, and amoebiasis.
This editorial summarizes many of the highlights of the new re-
search reported at the meeting.
2. Advances in antimalarial drug discovery and development
The need for low cost and effective anti-malarials against mul-
tidrug resistance Plasmodium falciparum has highlighted the need
for more diverse chemotypes and validated drug targets. Through-
out this meeting we heard of the approaches and results which
have been achieved since the last meeting in 2009.
Emily Derbyshire (Harvard Medical School) gave a comprehen-
sive account of the collaborative efforts of her work in Jon Clardy’s
lab (Harvard Medical School) with Maria Mota’s group (University
of Lisbon, Portugal) in disrupting liver stage development of malar-
ia parasites. A luminescence-based liver stage malaria assay wasPublished by Elsevier Ltd.
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Open acBased on known targets of the compounds, various cell receptors,
proton pumps and CDKs were predicted to have potential as drug
targets. The commercially available blood pressure drug, telmisar-
tan, was demonstrated to reduce parasitemia in a Plasmodium berg-
hei mouse model. The beneﬁts of re-purposing commercially
available drugs as liver stage speciﬁc therapeutics or research tools
were discussed.
The non-mevalonate pathway (MEP) pathway of isoprenoid
biosynthesis in P. falciparum, which is required for malaria parasite
growth, is the focus of the research interests of Audrey Odom
(Washington University, St. Louis). Isoprenoids are a diverse class
of biomolecules with multiple cellular functions, including roles
as co-factors and signaling molecules. Evidence supporting the
essentiality of the plasmodial enzyme IspD (methylerythritol phos-
phate cytidyltransferase) [Pf-IspD], and thus suitability of Pf-IspD
as a target, was provided and illustrated that it plays a key role
in metabolic control of Plasmodium parasites. The non-mevalonate
isoprenoid biosynthesis has been demonstrated to be important in
trophozoite and schizont stages in intraerythrocytic parasites and
in liver stage parasites. The antibiotic, fosmidomycin, has been
shown to block IspD in P. falciparum. A malachite green-based Pf-
IspD pilot screen of 1256 compounds was performed and novel
Pf-IspD inhibitors identiﬁed will be validated to conﬁrm activity
against the enzyme Pf-IspD, as well as conﬁrmation of activity
against the whole malaria parasite.
The development of the sexual stages, namely the gametocytes,
is required for transmission of malaria and thus an inability to com-
mit and progress to sexual development maymediate transmission
blockade. Andy Waters (University of Glasgow) indicated that the
production of gametocytes is an investment and a selective disad-
vantage for the asexually propagating parasite. He discussed how
sub-telomeric deletion on the species speciﬁc region of Chr9 wascess under CC BY-NC-ND license.
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of mutants of the ANKA line 820 of P. berghei that were unable to
produce gametocytes identiﬁed a gene that plays a central role in
gametocytogenesis. He also discussed ApiAP2 transcription factors
that are thought to drive the intraerythrocytic development cycle
gene expression cascade.
Dominic Hoepfner (Novartis) described the use of haploid insuf-
ﬁciency proﬁling (HIP HOP) for chemogenomic analysis in yeast.
Cladosporin is a potent antiplasmodial agent with 60 nM activity
against P. falciparum. The HIP HOP approach identiﬁed lysyl-tRNA
synthase as a target. In the identiﬁcation of point mutations, resis-
tance-conferring mutations are involved in the ATP–lysine interac-
tion. He also indicated that cladosporin showed the same inhibition
proﬁle as many established protein synthesis inhibitors. Results
from enzymatic assays conﬁrmed key residue speciﬁcity and clado-
sporin was shown to have a more potent IC50 on the P. falciparum
lysyl-tRNA synthetase than on the corresponding human homolog.
In addition, observed resistance was moderate and occurred at low
frequency, thus suggesting cladosporin has potential as a starting
point for novel anti-protozoan drugs.
Understanding host–parasite interactions in malaria is a focus
of the Greenbaum lab. In this context, Doron Greenbaum (Univer-
sity of Pennsylvania) discussed screening of small nonpeptidic
mimics of host defense proteins (HDP mimics) developed by
PolyMedix Inc., against P. falciparum. Lead compounds were found
to lyse the parasite digestive vacuole, but not the plasma mem-
brane of the parasite. Two compounds were tested in mice infected
with Plasmodium parasites and were able to signiﬁcantly lower
parasitemia.
Michael Riscoe (Oregon Health Sciences University) provided a
historical review of the discovery of chloroquine. This included the
research activities in the 1930s to identify an improved molecule
(sontochin) and the ultimate return to chloroquine due to its supe-
rior qualities. The need for low cost antimalarials, especially
against drug resistant forms of malaria, led Riscoe and colleagues
to re-evaluate the original chloroquine replacement drug. Finding
that sontochin retains signiﬁcant activity against chloroquine
resistant strains, he described their strategy to create sontochin
analogs. One of the highlighted analogs, PH-203, was at least 10
times more effective than chloroquine in vivo in treating infected
mice. Experiments suggest that enhancements in the metabolic
stability of this molecule will be needed to optimize the antimalar-
ial performance of this chemotype. This work focused attention on
the potential for development of low cost antimalarials using son-
tochin as a guide.
Anacor Pharamceuticals (San Franscico, CA) has a unique boron-
containing compound library which they are exploiting in their
quest for new anti-infectives. Dickon Alley presented several com-
pounds exhibiting potent antiparasitic and antifungal activity cur-
rently in preclinical development or clinical trials. One such
compound is AN3661, which has an IC50 value of 26 nM against
P. falciparum and is in preclinical development. Using AN2690 as
an example, he described how the unique mode of action of bor-
on-containing compounds has been applied to drug discovery.
Margaret Phillips (UT Southwestern Medical Center, Dallas) de-
scribed the dihydroorotate dehydrogenase (DHODH) inhibitor,
DSM74, which has been demonstrated to reduce parasitemia in a
P. berghei mouse model with no evidence of toxicity. These data
provided the ﬁrst proof-of-concept that DHODH inhibitors could
block parasite growth in vivo. It was indicated that the X-ray struc-
ture of PfDHODH in complex with representative triazolopyrimi-
dines was then used to facilitate the identiﬁcation of compounds
with improved potency and ADME properties. DSM265 was shown
to be a potent and selective inhibitor of the malaria enzyme, effec-
tive against both drug sensitive and resistant parasite strains, with
the compound having similar efﬁcacy to chloroquine in the SCIDmouse model of P. falciparum infection. Validation that DHODH
was the speciﬁc target for DSM265 and is an ideal antimalarial tar-
get was obtained through genetic rescue experiments. The syn-
thetic scheme for DSM265 is simple and inexpensive to
synthesize, and the compound has excellent oral bioavailability
and a long plasma half-life and low clearance. DSM265 is currently
in the preclinical development stage, and is part of the MMV
portfolio.
Geoffrey Dow (WRAIR) described the research program which
he has led for some years on Next Generation Quinolone Methanols
(NGQM) as potential intermittent preventative treatment (IPT) for
malaria in children and pregnant women, and prevention in travel-
lers. The neurological related side effects of meﬂoquine have lim-
ited the use of this drug (Dow et al., 2006). Geoff Dow presented
an overview of the project leading to WR621308 which, despite
heroic efforts, continued to retain too many of the adverse attri-
butes of the parent compound, ultimately resulting in the termina-
tion of the program (Milner et al., 2011).
Geoff McFadden (University of Melbourne, Australia) described
the metabolic pathways in the mitochondrion and apicoplast of the
malaria parasite as potential drug targets. In a genetic knockout of
P. berghei, the transmission of malaria to mice is blocked and the
ATPase-negative strain does not produce oocysts, ookinetes and
zygotes. However, the b subunit appears not to be essential in P.
berghei blood stage hence it was concluded that ATPase synthase
is not an optimal target. PfACCase knockout in the blood stages
of the parasite results in lack of malonyl-CoA production. Given
that neither PfACCase nor PbACCase have been demonstrated as
essential for the blood stages, it was concluded that these were
both poor therapeutic targets.
Thierry Diagana (NITD, Singapore) discussed the outcome of
projects from the NGBS consortium which had 2 goals (1) to dis-
cover a one dose cure for P. falciparum and (2) a curative modality
for Plasmodium vivax. A phenotypic SYBR green based HTS assay for
P. falciparum was used to undertake a screening campaign. Follow-
ing extensive lead optimization, NITD609 and GNF156, which are
both effective against P. falciparum, were identiﬁed as candidate
drugs. NITD609 has shown single dose cure in P. berghei and both
compounds have been demonstrated to block parasite transmis-
sion in a mouse model by pre-incubation of the compounds with
mature gametocytes. GNF156 also reduced parasitemia in a
humanized mouse model. NITD609 has been well described and
pharmacologically characterized, and is now entering phase II clin-
ical trials (Rottmann et al., 2010). It is anticipated that GNF156 will
start phase I trials in human by the end of 2012.
The challenge with achieving the second goal of a curative
modality for P. vivax, was the availability of a suitable assay for
the identiﬁcation of compound activity on the hypnozoite liver
stage. An overview of the development of the technology platform
required to support this aspect of the program was presented, and
the subsequent identiﬁcation of a novel antimalarial effective
against P. vivax.
A success story of the ozonide, OZ439, a peroxide based antima-
larial currently in clinical development, was presented by Susan
Charman (Monash University, Australia). Previous ﬁrst generation
ozonides such as OZ277 displayed potent antimalarial activity,
yet still had a relatively short half life in vivo. When OZ277 was
progressed to clinical trials, reduced plasma concentrations were
evident in malaria patients compared to concentrations seen in
healthy volunteers. This ﬁnding was believed to be caused by rapid
blood-mediated clearance in the presence of infection. Structural
modiﬁcations led to the discovery of new generation ozonides such
as OZ439 that maintained potent antimalarial activity and exhib-
ited cures with a single dose in animal models of malaria. Com-
pared to the earlier ozonides, OZ439 is considerably more stable
in non-infected and infected blood, and displays a much longer half
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and malaria patients. OZ439 is currently in Phase II clinical trials
(Charman et al., 2011).3. Advances in the understanding and impacts of drug
resistance by the malaria parasite
Any discussion on malaria drug development would be incom-
plete without addressing the concerns of drug resistance. The efﬁ-
cacy of every antimalarial drug in use today has been jeopardized
by the development drug resistance (Petersen et al., 2011). In fact,
the history of malarial drug developments parallels the history of
drug resistance development. Fears deepen as reports now indicate
that resistance is developing against the last remaining class of
antimalarial drugs, artemisinins. This urges the developing of
new antimalarial candidates currently in the pipeline and high-
lights the importance of expanding our knowledge of the molecu-
lar mechanisms associated with drug resistance. Future drug
candidates that are developed with the aim to circumvent or stall
resistance will help produce the next generation of therapies that
prevent or reduce mortality.
ThomasWellems from National Institutes of Health provided an
excellent overview of malaria drug resistance which highlighted
the hurdles that must be overcome with developing novel antima-
larial drugs. In particular, consideration should be given to drugs
that circumvent the drug-resistant transporters that are responsi-
ble for limited efﬁcacy of numerous antimalarial agents. Two
transporters that have been implicated in diminished efﬁcacy of
several antimalarial drugs are Pfcrt and Pfmdr1. Different resis-
tance mutation patterns in these transporters have been reported
in different part of the world reﬂecting differences in the history
of drug use. Laboratory engineered parasites by David Fidock
(Columbia University) and ﬁeld studies conducted by Philip Rosen-
thal (University of California, San Francisco) support the impor-
tance of evaluating drug transporters for drug efﬁcacy studies.
David Fidock reported on the drug sensitivity of genetically engi-
neered P. falciparum clones that express geographically-deﬁned
Pfcrt haplotypes from the Philippines and Cambodia. A correlation
exist between chloroquine resistance and a loss of parasite ﬁtness
in several areas, however an allele from Cambodia conferred high
level chloroquine resistance without diminishing ﬁtness suggest-
ing a strong transmission potential. Interestingly, biochemical
analysis suggests that although chloroquine efﬂux is a factor in
chloroquine resistance, it is not the sole explanation for Pfcrt-med-
iated chloroquine resistance. These studies highlight the geo-
graphic-speciﬁc evolution of Pfcrt haplotypes. The genetic lines
used in this study were resistant to amodiaquine but sensitive to
lumefantrine. Field studies conducted by Philip Rosenthal and col-
leagues in Uganda tracked diminished drug efﬁcacy via ex vivo sen-
sitivity testing and surveillance for acquisition of polymorphisms
in Pfmdr1 and Pfcrt. Particular emphasis was placed on the selec-
tive pressure induced by prior treatment with drug combination
regimens. It was observed that prior use of amodiaquine-contain-
ing therapies conferred a decrease in in vitro sensitivity and that
amodiaquine selected for the Pfmdr1 86Y and 1246Y, and Pfcrt
76T polymorphisms. This selection was not observed however if
prior therapy was with the artemether–lumefantrine combination,
which selected for Pfmdr1 N86 and D1246, and also for Pfcrt K76.
Thus, parasites are responding differently to the drug pressure ex-
erted by different artemisinin-based combinations.
An additional implication of transporters involved in artemisi-
nin combination therapy was presented by Leah Mwai (Kenya
Medical Research Institute). In this study, P. falciparum parasites
were induced and selected for in vitro lumefantrine resistance
and monitored the expression proﬁle of selected transporters. Inthese lines, 18 putative transporters, to include pfmdr1 and pfmrp,
displayed a differential expression pattern. Future studies aim to
characterize these transporters.
Artemisinin based drug combinations are commonly used
throughout the world as ﬁrst line treatment for uncomplicated P.
falciparum infection. Although highly effective at killing parasites,
recrudescence is a common problem associated with treatment.
Qin Cheng (Australian Army Malaria Institute) and in this issue
of IJPDDR, presented an evidence-based model as a possible expla-
nation for the high rate of recrudescence and relate recrudescence
to a stress-induced dormancy state. The model suggests that expo-
sure of ring-stage parasites to artemisinin, induces a dormant
growth stage that allows the parasites to tolerate the drug. Once
the drug is removed, parasites emerge from dormancy and con-
tinue to develop into mature parasites. Upon repeated exposure
to artemisinins, parasites may develop tolerance that neglects
the need to exist in the protective dormant state. In this regard,
tolerance to artemisinin may result in fewer dormant parasites
or faster recovery rates. In a clinical setting, this may translate to
a delay in parasite clearance times and/or an increase in the rate
of recrudescence. Dennis Kyle (University of South Florida) during
his keynote address reported the in vivo observation of artemisinin
induced dormancy. Additionally, the phenotype associated with
artemisinin resistance was reported. The induction of dormancy
appears to be linked to the artemisinin sensitivity of early ring-
stage parasites. Unfortunately the molecular mechanism responsi-
ble for dormancy induction and recovery are unknown however it
is believed that a cell cycle mechanism may be involved. Norman
Waters (United States Military Academy) presented evidence to
support a G1 cell cycle checkpoint during the early ring-stage
development. The checkpoint appears regulated by cyclin-depen-
dent protein kinases. A growth-retarded phenotype was observed
only when parasites were exposed to CDK inhibitors before the
breach of the checkpoint. In this regard, the G1 checkpoint may
control the ring to trophozoite transition. It remains to be deter-
mined if this checkpoint is responsive to environmental stress
and drug pressure.
The artemisinin mechanism of action is not fully understood
but oxidative stress mediated by hemoglobin digestion is believed
to play a key role (Meshnick, 1998). Leann Tilley (University of
Melbourne, Australia) reported evidence that artemisinin activity
is dependent on hemoglobin uptake and digestion. Hemoglobin
digestion begins 10–14 h following red blood cell invasion and
artemisinin sensitivity increases as the rate hemoglobin degrada-
tion increases. Treatment with artemisinin was shown to increase
the level of oxidative stress in the parasite cytoplasm. Disruption of
the hemoglobin degradation pathway by gene-knockout or enzy-
matic inhibition of the hemoglobinase falcipain-2 resulted in a de-
crease in the level of oxidative stress and a decrease in parasite
killing. Sub-lethal doses of artemisinin retarded parasite growth
and reduced the rate of hemoglobin uptake. The evidence is indic-
ative that P. falciparum growth and metabolism are responsive to
artemisinin treatment, although the signaling pathways and
molecular machinery responsible for these artemisinin-induced re-
sponses are unknown. An enhanced ability to suspend hemoglobin
digestion could lead to artemisinin tolerance. Oxidative stress is
believed to play a key role in the antimalarial activity of artemisi-
nins. As reported by Warangkhana Songsungthong, disruption of
the glutathione (an intracellular antioxidant) biosynthetic pathway
in P. berghei increased sensitivity to artesunate and pyrimeth-
amine. The consequence of oxidative stress provides insight and
rationale that should be considered for the development of antima-
larial drug combinations.
Progress reported by Dylan Pillai (University of Calgary, Canada)
continued the theme of characterizing and inhibiting enzymes that
may potentiate the efﬁcacy of existing antimalarial drugs and
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induced chaperone and cell cycle regulator in the malaria parasite
was shown to interact with Pfcrt. The PfHsp90 inhibitor, PU H71, is
a potent antimalarial agent that synergizes with chloroquine and
was able to reverse chloroquine resistance. Similar results were ob-
tained from either a cell based assay or in the P. berghei mouse
model. These ﬁndings support PfHsp90 inhibitors as a viable part-
ner for the development of drug combination therapies.
Two independent groups reported efforts to elucidate the
molecular mechanisms for the acquisition of drug resistance. Pra-
dipsinh Rathod (University of Washington) presented new data
from his team on how parasites with ARMD (Accelerated Resis-
tance to Multiple Drugs) phenotype may initiate drug resistance.
Resistance to the PfDHODH inhibitor, DSM1, invariably resulted
in ampliﬁcation of a fragment on chromosome 6 which contained
the PfDHODH gene. Dr. Rathod illustrated how this system could be
used to study these early steps of the initiation of drug resistance
and the various factors that may determine whether the outcome
would be stable or not, with and without drug pressure. Geoffrey
Siwo (University of Notre Dame) reported studies to exploit the
genomic alterations acquired by chloroquine resistant malaria par-
asites in predicting vulnerable parasite pathways. Using a systems
biology approach to test the hypothesis that genomes are ‘‘re-
wired’’ in response to drug pressure, comparison between chloro-
quine resistant and sensitive genomes predicted targets that
would respond to inhibitor treatment. The essence of the approach
is to compare the differential co-expression patterns of the se-
lected target to that of Pfcrt. In proof-of-concept examples, accu-
rate predictions were made for the effectiveness of inhibitors on
ferrochelatase (heme biosynthesis) and a MutS homolog (DNA re-
pair). Collectively these studies demonstrate that genomic tools,
alongside tailored in vitro growth inhibition assays, can provide a
fuller understanding of the mechanism of drug resistance and pre-
dict drug susceptibility.
The development of drug resistance and the associated implica-
tions for morbidity and mortality caused by P. falciparum is appar-
ent; however there are other species of parasites causing malaria
that have been neglected. Kevin Baird (Eijkman-Oxford Clinical Re-
search Unit, Indonesia) highlighted P. vivax as ‘‘the neglected ma-
laria parasite’’ even though this parasite is responsible for 100–
400 million infections per year, of which an as yet unknown pro-
portion are severe or fatal: 24% and 8% in one study in Indonesia.
P. vivax resistance to chloroquine (blood schizontocide) and pri-
maquine (hypnozoitocide) has developed and for chloroquine, ap-
pears to be widespread throughout Southeast Asia. Unfortunately,
unlike chloroquine resistance in P. falciparum, the mechanism of
resistance in P. vivax is unknown. Efforts must be initiated and sup-
ported to develop novel therapies for P. vivax. However, any new
therapies to replace chloroquine must be evaluated with primaqu-
ine since the latter is the only drug available to clear hypnozoites,
the source of relapses. Evidence presented suggests primaquine re-
quires an appropriate co-drug to be efﬁcacious. In this regard, new
therapies designed for P. vivax must be a pursued as a drug combi-
nation endeavor, not only due to drug resistance but because of the
need to address the diverse parasite forms occurring during the life
cycle of the P. vivax infection. In this issue of IJPDDR, Kevin Baird
expands on the challenges ahead for chemotherapeutic discovery
and highlights the need to develop therapeutic strategies for not
only P. falciparum, but also for all malaria species. Furthermore,
any discussion concerning malaria elimination and control must
include endemic malaria which is often difﬁcult to diagnose and
ineffectively treated.
Alyson Auliff (Australian Army Malaria Institute) reported the
development of a transgenic system in which wild-type and mu-
tant P. vivax dhfr genes are stably expressed in P. falciparum and
used to assess the effect of current and new antifolate drugs. Dueto the difﬁculties of culturing P. vivax, the transgenic expression
system has the potential to support drug discovery efforts for spe-
ciﬁc vivax targets and provide a system to characterize the molec-
ular mechanisms responsible for drug resistance. Karryn Gresty
(Australian Army Malaria Institute Paciﬁc Malaria Initiative) re-
ported the surveillance of P. vivax infection and genotypic studies
of samples collected throughout the South Paciﬁc. It is envisioned
that the development of molecular tools, assays and culturing
techniques will soon complement ongoing surveillance efforts to
better understand the evolution and dynamics of P. vivax drug
resistance.4. Advances in drug development for other protozoan
pathogens
Human African trypanosomiasis (HAT) remains a serious public
health problem in regions of sub-Saharan African and antitrypan-
osomal drugs are severely limited by poor efﬁcacy, toxicity, and
costs. Efforts by the research community to discover new treat-
ments for HAT depend on efﬁcient and effective screening methods
of compound libraries. The identiﬁcation and characterization of
‘‘hit’’ compounds against Trypanosoma brucei has been greatly
facilitated by techniques reported by Bowling et al. in this issue
of IJPDDR that are amenable to high-throughput screening plat-
forms. Using the ﬂuorometric dye, resazurin, the investigators per-
formed a screen of a nearly 48,000 compound library with
excellent Z0 scores in the 0.7–0.9 range. The screen has led to six
distinct chemical series for subsequent hit-to-lead development.
In addition, the authors describe methods for examining the effects
of serum binding on the antitrypanosomal activity of compounds
as well as techniques for measuring time-to-kill and reversibility
of the compounds’ activities, all of which provide important infor-
mation for prioritizing compounds for subsequent investigation.
Bakela Nare representing the same group at Scynexis Inc., also
presented an update on the development of oxaborole compounds
for HAT. The best of these low molecular weight, boron containing
compounds demonstrated curative activity in the stringent late-
stage mouse model of infection where the parasites were cleared
from the central nervous system. By combining excellent pharma-
cokinetic stability with the ability to cross into the central nervous
system, these antitrypanosomal compounds have properties that
make them excellent clinical candidates for treating late-stage
HAT. The lead compound SCYX-7158 is presently in Phase I clinical
trials where human pharmacokinetics and safety will determine
the potential to progress the compound into ﬁeld studies for HAT.
Paul Wyatt from the Drug Discovery Unit at the University of
Dundee reported on progress in targeting the N-myristoyltransfer-
ase enzyme for anti- T. brucei chemotherapy. RNA interference
demonstrates the essentiality of the target, and high-throughput
screening followed by lead-optimization led to a sulfonamide com-
pound with highly potent EC50 values of 2 nM. The compound
cured mice with early-stage trypanosomiasis and related com-
pounds cured late stage disease in mice lacking PgP drug efﬂux
pumps. However, compounds with better ability to penetrate the
CNS will be necessary to cure the late stage of the disease.
Other biochemical targets inT. brucei that were reported to have
potential to be exploited for drug therapy include the aurora
kinase, methionine aminopeptidase, methylthioadenosine phos-
phorylase, nucleotide metabolism, the RNA editing ligase, and the
methionyl-tRNA synthetase. Christophe Verlinde (University of
Washington) reported new compounds targeting the latter target
with evidence for excellent brain permeability, thus having poten-
tial for treating late-stage African trypanosomiasis.
American trypanosomiasis, commonly called Chagas disease, is
widespread throughout Latin America and has a growing impact
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infection have settled in large numbers. As with HAT, the anti-par-
asitic treatments for American trypanosomiasis are unsatisfactory
due to poor efﬁcacy and high toxicity. In this issue of IJPDDR, Buck-
ner and Urbina summarize developments in exploiting sterol bio-
synthesis inhibitors as anti-Trypanosoma cruzi agents. The P450
enzyme, sterol 14-demethylase, has been investigated extensively.
Antifungal drugs in the azole class target sterol 14-demethylase
and have activity on the T. cruzi orthologue. The clinical drug, posa-
conazole, has sub-nanomolar activity on T. cruzi cultures and cures
the stringent chronic mouse model of T. cruzi infection. Clinical tri-
als in Spain and Argentina are currently underway to assess the po-
tential for repurposing this antifungal drug for this protozoan
disease. Similarly, another sterol 14-demethylase inhibitor, an oral
prodrug of ravuconazole (developed by Eisai Pharmaceuticals
through phase II studies for fungal infections) is entering clinical
trials for Chagas disease in Bolivia under the auspices of the Drugs
for Neglected Diseases Initiative. At the symposium, Buckner (Uni-
versity of Washington, Seattle, WA) presented data on analogs of
the anti-cancer clinical candidate, tipifarnib. This class of sterol
14-demethylase inhibitors has subnanomolar activity against T.
cruzi in vitro along with the advantage of having low activity
against human liver CYP enzymes that improve its potential for
safety compared to other sterol 14-demethylase inhibitors.
To facilitate drug discovery against T. cruzi, Melissa Sykes (Grif-
ﬁth University, Queensland, Australia) described a 384-well imag-
ing assay employing the use of cytoplasmic and nuclear markers
that allows the simultaneous determination of activity on both T.
cruzi-infected and non-infected host cells. The advantage of this
technique is that it allows the screeners to assess both the antipar-
asitic activity and the host-cell cytotoxicity in a single high-
throughput assay.
Maria Papadopoulou (Northshore University, Evanston, IL)
presented data utilizing luciferase expressing T. cruzi for biolumi-
nescent imaging of infected mice to assess the activity of investiga-
tional compounds. This work led to the discovery of novel 3-nitro-
1,2,4-triazole-based compounds with potent activity in the mouse
model of T. cruzi infection. Another area of interest was research re-
ported by Denise da Gama Jaen Batista (Institute Oswaldo Cruz, Rio
de Janeiro, Brazil) looking at combination chemotherapy for T. cruzi
infection. In particular, the group described combining the standard
T. cruzi drug, benznidazole, with diamidine compounds (known for
potent anti-T. brucei activity) and showed signiﬁcantly enhanced
the activity of over either compound used alone. The studies rein-
force the idea that combination chemotherapy may be crucial for
developing optimal treatment regimens for treating Chagas disease.
As with T. brucei, compounds targeting the N-myristoyltransfer-
ase were tested for anti-T. cruzi activity as reported by Linda
Herrera of Rosa Maldonado’s group (University of Texas El Paso).
The unpublished data showed that the compounds have submi-
cromolar activity against intracellular cultures of T. cruzi.
Another kinetoplastid organism, Leishmania, was the topic of
several presentations at the meeting. Causing cutaneous, mucocu-
taneous, or visceral leishmaniasis, species of Leishmania threaten
the health of people living in 88 countries. The existing drugs are
limited by problems such as widespread resistance, parenteral
routes of administration, toxicity, and/or teratogenicity. To address
the shortcoming in anti-leishmanial therapeutics, scientists at The
Ohio State University represented by Mark Drew screened a com-
pound library and discovered a potent hit in the berberine class. A
semisynthetic berberine analog had potent anti-leishmanial
activity in vitro with a therapeutic window >270-fold against
mammalian cells. The compounds decrease the liver burden of
Leishmania donovani in mice by nearly 50%. The target of action
is unclear, but the series appears to have broad spectrum activity
against protozoa including other trypanosomes and Plasmodium.The group at the Sandler Center represented by De Muylder
(University of California, San Francisco) has developed a high-con-
tent cell-based screening assay for L. donovani and reported results
from a pilot screen of 900+ bioactive compounds. Drug discovery
for visceral leishmaniasis has been particularly hampered by
low-throughput methodologies, so this research represents a sig-
niﬁcant advance to help accelerated drug discovery against this
pathogen.
The enteric protozoan, Entamoeba histolytica, is responsible for
almost 100,000 deaths per year worldwide, only second to malar-
ia as a cause of mortality by protozoan pathogens. In this issue of
IJPDDR, Abhyankar et al. (University of Virginia, Charlottesville,
VA) provide new data on a remarkable class of transmembrane
kinases of which there are over 100 in E. histolytica. These pro-
teins are believed to serve as signaling molecules especially at
the parasite-host interface. By decreasing expression levels of
one transmembrane kinase (EhTMKB1-9), the investigators
showed lower levels of phagocytosis and endocytosis under
experimental conditions. Overexpression of a mutant form of
EhTMKB1-9 lacking the kinase domain resulted in a competitive
disadvantage with regard to survival in the mouse gut, however,
these parasites were still able to form abscesses in the liver ab-
scess model in gerbils. Transmembrane kinases are viewed as po-
tential drug targets for E. histolytica due to their apparent role in
virulence and proliferation.
A presentation by Rosa Andrade (University of California, San
Diego) described anti-Entamoeba spp in vitro activity of a drug ap-
proved for use in rheumatoid arthritis (auranoﬁn). The IC50 of
auranoﬁn against E. histolytica trophozoites was 2 lM. Of note,
auranoﬁn had much higher cysticidal activity on Entamoeba inva-
dens cysts than the standard amoebocide, metronidazole, provid-
ing a potential therapeutic advantage. As an FDA approved drug,
auranoﬁn has potential to be advanced into clinical studies for
amoebiasis much more rapidly than non-approved compounds.
On a similar note, the strategy of repurposing FDA approved
drugs for anti-protozoan applications was described for the enteric
pathogen, Cryptosporidium parvum. Kovi Bessof (University of Ver-
mont) developed a high-throughput screening platform for C. par-
vum then screened a collection of 727 approved or drug-like
molecules both alone or in combination with nitazoxanide (an
establish anti-Cryptosporidium drug). Hits from this screen are
being further evaluation alone or in combinations in immunocom-
promised animals with C. parvum infection.
Finally, the agent of amoebic meningoencephalitis, Naegleria
fowleri, was the subject of investigations by Anjan Debnath (Uni-
versity of California, San Francisco). An in vitro high-throughput
screening platform was developed, and used against a library of
FDA-approved drugs and drugs in clinical development. A polyene
antifungal drug similar to amphotericin B, called corifungin, was
identiﬁed in the screen and determined to have excellent activity
(better than amphotericin B) in a mouse model of primary amebic
meningoencephalitis. Based on these results, the FDA has approved
an Orphan-Drug status of corifungin for treatment of primary ame-
bic meningoencephalitis.5. Concluding remarks
The Keystone Symposium on ‘‘Drug Discovery for Protozoan
Parasites’’ provided an extraordinary opportunity to engage indi-
viduals in all aspects of protozoan drug development. Parasitolo-
gists, medicinal chemists and clinicians from academia, industry
and governmental institutions shared a common goal of reducing
the burden of protozoan diseases. There are many problems and
hurdles to overcome in drug development; however this confer-
ence promoted the discussions of obstacles unique to protozoan
F.S. Buckner et al. / International Journal for Parasitology: Drugs and Drug Resistance 2 (2012) 230–235 235drug development. Momentum from this conference will advance
drug development efforts as new collaborations were made and
unpublished data revealed.
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